Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients.
BACKGROUND
Several preventive strategies against cytomegalovirus (CMV) disease have been developed during the last decade. These have frequently been used in combination, and it has been difficult to identify each strategy's contribution.


METHODS
Risk factors for CMV disease, death in CMV disease and transplant-related mortality were analyzed in 584 patients, who underwent a total of 594 allogeneic bone marrow transplants.


RESULTS
The overall probability of CMV disease was 8.9%. No seronegative patient who had a seronegative marrow donor developed CMV disease. The corresponding probabilities for seronegative patients with seropositive donors, seropositive patients with seronegative donors, and seropositive patients with seropositive donors were 5.4%, 13.7%, and 11.7%, respectively. In multivariate Cox models, the use of preemptive antiviral therapy and being CMV-seronegative reduced the risk for CMV disease, CMV-associated death, and transplant-related mortality (TRM). Patients who received unrelated or mismatched family donor transplants had increased risks for CMV disease, CMV-associated death, and TRM. Older age was a significant risk factor for CMV disease and TRM. A total of 258 patients who were monitored by polymerase chain reaction for CMV DNA were analyzed separately to assess whether addition of another CMV preventive strategy could give benefit. Patients who received mismatched or unrelated donor transplants had increased risk for CMV disease, death in CMV disease, and TRM. High-dose acyclovir prophylaxis or addition of intravenous immune globulin had no influence.


CONCLUSIONS
Preemptive therapy based on polymerase chain reaction for CMV DNA was associated with reduced risks for CMV disease, CMV-associated death, and TRM, whereas other prophylactic modalities did not give additional benefit.
Ljungman
P
P
Department of Hematology, Huddinge University Hospital, Karolinska Institutet, Sweden. per.ljungman@medhs.ki.se
Aschan
J
J
Lewensohn-Fuchs
I
I
Carlens
S
S
Larsson
K
K
Lönnqvist
B
B
Mattsson
J
J
Sparrelid
E
E
Winiarski
J
J
Ringdén
O
O
D000212:Acyclovir / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D001853:Bone Marrow / Q000821:virology; D016026:Bone Marrow Transplantation / Q000401:mortality*; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000401:mortality / Q000517:prevention & control; D017245:Foscarnet / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D007223:Infant; D008875:Middle Aged; D015999:Multivariate Analysis; D014019:Tissue Donors
D000998:Antiviral Agents; D017245:Foscarnet; D000212:Acyclovir